Biotechnology

A high-profile Washington gala reveals the strategic maneuvering of biotechnology startups navigating the multibillion-dollar early cancer detection market.

By leveraging deuterated chemistry, Aviva Bio aims to bypass the oncologic risks that have stalled FDA approval for female testosterone therapies for decades.

MindWalk’s successful deployment of OpenFold3 on AMD and Vultr proves that alternative silicon and open-source models are ready for enterprise biopharma.

With standard-of-care avacopan facing global regulatory withdrawal, InflaRx is stepping into the void. A strategic look at the upcoming Capital Markets Day and the mechanics of clinical resilience.

Cellular Intelligence assembles a powerhouse advisory board and acquires a Phase 2 Parkinson's therapy to build the first universal model of cell signaling.

As diabetic amputations rise globally, a micro-cap biotech enters Phase 2a trials with a novel topical gel designed to physically destroy drug-resistant superbugs.

As the biosimilar wave hits rare diseases, Sandoz and mAbxience join forces to develop a complex bispecific alternative to Roche's $5.7B blockbuster Hemlibra.

Matisse Pharmaceuticals secures €14 million to advance a radically different approach to sepsis, targeting cytotoxic histones to stop organ failure.

Heavy menstrual bleeding drives 600,000 surgeries a year. Hemab Therapeutics aims to replace invasive treatments with a once-a-month injection.

SK Biopharmaceuticals and 1ST Biotherapeutics forge a $314.8M alliance to advance a novel dual-inhibitor, reshaping the global Parkinson's landscape.

As personalized therapies fragment drug production into small batches, a new flexible dispensing system aims to eliminate bioprocessing's costly QC bottlenecks.

The strategic alliance between ProBio and Kun Tuo signals a shift in how global biopharma navigates the fragmented cell and gene therapy clinical landscape.

NanoTess co-founders Megan Leslie and Julian Mulia win Canada's Top 40 Under 40 for a catalytic technology that addresses a massive healthcare crisis.

For 30 years, hair loss treatments have been trapped in a hormonal stalemate. Rubedo Life Sciences is betting its AI-driven senolytic platform can change that.

A new transpacific partnership between Cellares and GenomeFrontier signals a critical shift in cell therapy, swapping viral vectors for automated precision.

Digital therapeutics 1.0 crashed and burned. By fusing software directly with standard prescriptions, a new hybrid model is rewriting the pharma playbook.

A novel non-viral gene therapy shows early promise in treating Geographic Atrophy, targeting the root cause of iron overload to potentially reverse vision loss.

After decades of setbacks, a new drug from Skyhawk Therapeutics shows patients not just slowing decline, but improving. Is this the breakthrough a desperate community has been waiting for?

GT Biopharma secures FDA clearance for a Phase 1 trial of GTB-5550 in multiple myeloma, a strategic pivot for its TriKE® platform, but the trial's start hinges on securing grant funding.

RegCell just raised $66M to advance its Nobel-winning Treg therapy. Can it move beyond broad immunosuppression and truly reset the body's immune system?